Among the three stocks highlighted in today’s article where analysts at RBC see upside potential over 100% – and which have all earned “Strong Buy” consensus analyst ratings – is “a pharmaceutical company with a unique niche.
The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason? Their respective COVID-19 vaccine development programs, which have moved at lightning-fast speed.
“The fact that more than 9 months of this year have been focused on the space is unfounded. In fact, I don’t remember one industry in recent history that has so captivated the stock market as much as this,” says the author of today’s article of the biotech space – and biotech penny stocks in particular.
Three biotech companies developing therapies for the treatment of cancer and other diseases – including infectious diseases like COVID-19 – began trading on Friday.
A trio of biotech firms IPOed on Friday – and saw double-digit gains on their trading debuts.
Which biotech stocks will be the next to reward risk-tolerant investors with massive returns?
Biotech Start-ups poised to take off in the next 12 months.